For all Quality Assurance Persons working with Natural Health Products, it is important that certain tasks are done regularly to ensure an importer or site license holder can meet Canadian standards. Health Canada is constantly updating their GMP requirements for the site license process and it remains important to be aware of their expectations for GMP documentation as maintain site licenses are vital for any parties interested in importing and manufacturing Natural Health Products in Canada.
Health Canada requires Natural Health Products sold in Canada to have a product licence, generally identified by a Natural Product Number (NPN) or, for homeopathic medicines, a DIN-HM. Applicants must provide evidence supporting the product’s safety, efficacy, and quality, including its medicinal ingredients, recommended conditions of use, and relevant quality controls. Any Quality Assurance Person must ensure all importing and manufacturing documents match how the product was registered.
What Are Some Recent Changes That Health Canada Has Made?
Health Canada has introduced several important regulatory and administrative changes affecting NHP licence holders:
- Updated GMP guidance: Version 4.0 of the Good Manufacturing Practices Guide for Natural Health Products (GUI-0158) was published on September 4, 2025, and took effect on March 4, 2026. It clarifies expectations for quality systems, specifications, and GMP implementation.
- Changes to finished product specification submissions: Effective June 15, 2026, applicants no longer need to submit Finished Product Specifications (FPS) with Class II and Class III product licence applications or amendments. Class I applications already had this exemption. However, licence holders must still establish, maintain, and provide FPS to Health Canada upon request.
What is needed for Finished Product Specifications?
Finished Product Specifications are documented quality standards that define the acceptance criteria a finished NHP must meet before release and throughout its shelf life, as applicable. They must be scientifically justified, product-specific, and consistent with the product’s authorized conditions of use.
A comprehensive FPS framework should address the following:
- Identity: Evidence that the product and its medicinal ingredients are correctly identified.
- Quantity and potency: Appropriate limits for medicinal ingredients, including declared quantities and relevant active constituents.
- Purity: Controls for contaminants and impurities, including microbial contamination, heavy metals, pesticides, or residual solvents where applicable.
- Physical and chemical characteristics: Relevant attributes such as appearance, dosage form, pH, or other parameters that affect product quality.
- Testing methods and acceptance criteria: Suitable, validated or otherwise appropriately qualified methods, with defined limits and justified testing approaches.
The specific tests and limits depend on the ingredients, dosage form, formulation, and product risks. Health Canada’s Quality of Natural Health Products Guide and FPS guidance provide the relevant technical framework.
Although FPS submission requirements have changed, the obligation to maintain complete specifications, testing records, and supporting quality evidence remains. Health Canada may review this information during inspections, site licence assessments, or post-market compliance activities.
Why Must Quality Assurance Persons Pay Attention to Specifications?
The Quality Assurance Person (QAP) plays a central role in ensuring that NHPs consistently meet regulatory and quality requirements. Under the GMP framework, product specifications and any changes to them must be approved by a QAP.
QAPs should ensure that:
- Specifications are accurate, current, scientifically justified, and aligned with the product licence and applicable regulatory requirements.
- Testing procedures, sampling plans, and acceptance criteria are suitable for the product and consistently applied.
- Out-of-specification (OOS) results are investigated, documented, and resolved through appropriate corrective and preventive actions (CAPA).
- Changes to ingredients, suppliers, manufacturing processes, analytical methods, or packaging are assessed for their impact on product quality and regulatory compliance.
- Batch records, test results, stability data, and product-release decisions are complete, traceable, and readily available for inspection.
Conclusion
Successful NHP compliance requires an integrated approach to product licensing, site licensing, and GMP quality management. Recent Health Canada changes have streamlined certain submission processes, but licence holders remain responsible for demonstrating that their products meet established quality standards and that their sites maintain the required GMP controls.
For consultants and regulatory professionals, the priority is to maintain current licensing documentation, prepare for site licence renewals well in advance, and ensure that FPS remain scientifically sound, properly approved, and supported by reliable testing and stability records.
Blog Author
Matthew Lai
Matthew holds a B.Sc. in Honours Biology from the University of Waterloo and a Certificate in Regulatory Affairs from Humber College, where he developed a strong interest in Quality Assurance and the regulatory standards for medical devices, drugs, and natural health products. With nearly 4 years of experience, Matthew has been working closely with clients interested in manufacturing or importing Natural Health Products.
